BidaskClub upgraded shares of FibroGen (NASDAQ:FGEN) from a sell rating to a hold rating in a research report report published on Tuesday, BidAskClub reports.
Several other equities research analysts have also commented on the company. Goldman Sachs Group restated a neutral rating and set a $45.00 target price on shares of FibroGen in a research report on Wednesday, May 29th. TheStreet lowered FibroGen from a c- rating to a d+ rating in a research report on Friday, May 24th. Piper Jaffray Companies restated a positive rating and set a $40.00 target price (down previously from $65.00) on shares of FibroGen in a research report on Monday, May 27th. Zacks Investment Research lowered FibroGen from a buy rating to a hold rating in a research report on Wednesday, May 15th. Finally, ValuEngine lowered FibroGen from a buy rating to a hold rating in a research report on Friday, May 10th. Five analysts have rated the stock with a hold rating and five have given a buy rating to the company. FibroGen currently has a consensus rating of Buy and a consensus target price of $61.57.
Shares of FibroGen stock opened at $41.33 on Tuesday. FibroGen has a one year low of $33.51 and a one year high of $68.55. The company has a debt-to-equity ratio of 0.09, a quick ratio of 6.16 and a current ratio of 6.16. The stock has a market cap of $3.46 billion, a P/E ratio of -40.13 and a beta of 1.75.
FibroGen (NASDAQ:FGEN) last announced its earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.53) EPS for the quarter, beating the consensus estimate of ($0.68) by $0.15. FibroGen had a negative return on equity of 17.71% and a negative net margin of 44.14%. The company had revenue of $23.90 million for the quarter, compared to analyst estimates of $20.44 million. During the same quarter in the prior year, the company earned ($0.50) EPS. The firm’s revenue for the quarter was down 25.1% compared to the same quarter last year. Equities research analysts expect that FibroGen will post -0.87 earnings per share for the current fiscal year.
In other FibroGen news, SVP Pat Cotroneo sold 7,665 shares of the stock in a transaction that occurred on Tuesday, March 19th. The stock was sold at an average price of $55.41, for a total value of $424,717.65. Following the transaction, the senior vice president now owns 239,504 shares in the company, valued at $13,270,916.64. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO Thomas B. Neff sold 39,636 shares of the stock in a transaction that occurred on Thursday, March 21st. The stock was sold at an average price of $55.52, for a total value of $2,200,590.72. Following the completion of the transaction, the chief executive officer now owns 2,596,440 shares in the company, valued at approximately $144,154,348.80. The disclosure for this sale can be found here. In the last quarter, insiders sold 251,495 shares of company stock worth $11,234,313. Corporate insiders own 8.96% of the company’s stock.
Large investors have recently made changes to their positions in the business. Lindbrook Capital LLC boosted its holdings in FibroGen by 150.0% in the first quarter. Lindbrook Capital LLC now owns 500 shares of the biopharmaceutical company’s stock worth $27,000 after acquiring an additional 300 shares in the last quarter. FTB Advisors Inc. bought a new position in FibroGen in the first quarter worth approximately $27,000. Manchester Capital Management LLC bought a new position in FibroGen in the first quarter worth approximately $39,000. Cornerstone Advisors Inc. boosted its holdings in FibroGen by 672.8% in the first quarter. Cornerstone Advisors Inc. now owns 796 shares of the biopharmaceutical company’s stock worth $43,000 after acquiring an additional 693 shares in the last quarter. Finally, Flinton Capital Management LLC bought a new position in FibroGen in the fourth quarter worth approximately $44,000. Institutional investors and hedge funds own 66.27% of the company’s stock.
FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States and Europe; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.
Read More: Why do commodities matter?
Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.